title: [Immunovac-VP-4 for prevention of acute respiratory diseases in children's communities].
abstract: OBJECTIVE
  Assessment of prophylactic effect of Immunovac-VP-4 against acute respiratory diseases (ARDs) in collectives of children.
  
  
  METHODS
  Immunovac-VP-4 was used for prophylaxis of ARDs in communities of children (daycare centers, boarding school). During 3 consecutive controlled studies performed during peak incidence of epidemic influenza and ARD (1st study) and during pre-epidemic period (2nd and 3rd studies) the incidence of ARDs was studied in groups of vaccinated and non-vaccinated children. Criteria for assessment of ARDs incidence and their severity were as follows: number of ARD episodes per child, number of children with recurrent episodes of ARD during period of follow-up, duration of ARDs, and number of children with bacterial complications (bronchitis, otitis, etc.). Effect of intervention on immunologic parameters was assessed on levels of sIgA, IgG, IgA, and antibody titers in saliva. Schedule of vaccine administration was 3 daily intranasal and 6 - 9 oral administration of the vaccine with 3 - 4 days interval.
  
  
  RESULTS
  Results of all three studies were virtually the same: decrease of number of ARD episodes and their duration; 3.1-fold reduction of number of children with recurrent infections during 14 months of follow-up, and 10.9--12-fold reduction during first 7 months of follow-up; decrease of bacterial complications rate (1.9% in children in intervention group, 11.9%--in control group). Increase of total immunoglobulin level and antibody titers to antigenic components of the vaccine from low baseline level was observed in saliva of vaccinated children.
  
  
  CONCLUSIONS
  Immunovac-VP-4 results in enhanced and prolonged prophylactic effect on ARDs incidence and recommended for building of optimal system of prevention of polyetiologic complex of ARDs.
authors.forename: N B
authors.initials: NB
authors.lastname: Egorova
authors.forename: E A
authors.initials: EA
authors.lastname: Kurbatova
authors.forename: I M
authors.initials: IM
authors.lastname: Gruber
authors.forename: I B
authors.initials: IB
authors.lastname: Semenova
mesh_terms: D000208:Acute Disease; D000281:Administration, Intranasal; D000284:Administration, Oral; D000907:Antibodies, Bacterial / Q000032:analysis; D000942:Antigens, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D002648:Child; D002656:Child Day Care Centers; D002675:Child, Preschool; D004926:Escherichia coli / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000276:immunology; D007711:Klebsiella pneumoniae / Q000276:immunology; D011514:Proteus vulgaris / Q000276:immunology; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control*; D012463:Saliva / Q000276:immunology; D013211:Staphylococcus aureus / Q000276:immunology; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D007070:Immunoglobulin A; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D007155:Immunologic Factors